^
    3ms
    Exploring DNA topoisomerase II alpha in adrenocortical carcinoma through multi-omics analysis: a potential biomarker and therapeutic target. (PubMed, Acta Biochim Biophys Sin (Shanghai))
    Potential inhibitors targeting TOP2A are discovered, and the therapeutic effects of resminostat and etoposide are confirmed via in vivo assays, suggesting new therapeutic strategies for ACC treatment. In conclusion, TOP2A serves as a crucial biomarker in ACC and is associated with adverse clinical outcomes and a diminished immune response. The identification of potential inhibitors against TOP2A opens new avenues for the development of targeted therapies for ACC patients.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • TOP2A (DNA topoisomerase 2-alpha)
    |
    etoposide IV • Kinselby (resminostat)
    over1year
    RESMAIN: Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) (clinicaltrials.gov)
    P2, N=201, Completed, 4SC AG | Active, not recruiting --> Completed
    Trial completion
    |
    Kinselby (resminostat)
    over4years
    Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma. (PubMed, Sci Rep)
    In addition, the drug combination decreased phosphorylated ERK level, indicating inhibition of the mitogenic signaling pathway MEK/ERK. Taken together, the resminostat plus sorafenib combination counteracts platelet-mediated cancer promoting effects in HCC cells.
    Journal • Combination therapy • Epigenetic controller
    |
    CD44 (CD44 Molecule)
    |
    CD44 expression
    |
    sorafenib • Kinselby (resminostat)
    over4years
    Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma. (PubMed, PLoS One)
    The JAKi/HDACi combination exhibited substantial anti-tumor effects in CTCL cell lines, and may represent a promising novel therapeutic modality for CTCL patients.
    Journal
    |
    JAK2 (Janus kinase 2) • JAK1 (Janus Kinase 1) • STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    Jakafi (ruxolitinib) • Kinselby (resminostat)
    5years
    Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism. (PubMed, J Med Invest)
    In comparison with PC-9 cells, PC-9 BIMi2- / - cells were less sensitive to apoptosis mediated by EGFR-TKIs such as gefitinib and osimertinib. Invest. 67 : 343-350, August, 2020.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • BCL2L11 deletion
    |
    Tagrisso (osimertinib) • gefitinib • Kinselby (resminostat)